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Abstract
Whether iron deposition is an epiphenomenon of the multiple sclerosis (MS) disease process or may play a primary
role in triggering inflammation and disease development remains unclear at this time, and should be studied at
the early stages of disease pathogenesis. However, it is difficult to study the relationship between iron deposition
and inflammation in early MS due to the delay between the onset of symptoms and diagnosis, and the poor
availability of tissue specimens. In a recent article published in BMC Neuroscience, Williams et al. investigated the
relationship between inflammation and iron deposition using an original animal model labeled as “cerebral
experimental autoimmune encephalomyelitis”, which develops CNS perivascular iron deposits. However, the relative
contribution of iron deposition vs. inflammation in the pathogenesis and progression of MS remains unknown.
Further studies should establish the association between inflammation, reduced blood flow, iron deposition,
microglia activation and neurodegeneration. Creating a representative animal model that can study independently
such relationship will be the key factor in this endeavor.
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At this time it is unclear whether iron deposition is an
epiphenomenon of the multiple sclerosis (MS) disease
process or may play a primary role in triggering inflam-
mation and disease development [1]. However, it is diffi-
cult to study the relationship between iron deposition
and inflammation in early stages of MS due to the delay
between the onset of symptoms and diagnosis, and the
poor availability of early tissue specimens.
In a recent article published in BMC Neuroscience,
Williams et al. [2] investigated the relationship between
inflammation and iron deposition using an original
animal model labeled as “cerebral experimental autoim-
mune encephalomyelitis”, which develops CNS perivas-
cular iron deposits.
Iron plays an essential role in normal neurobiological
functioning, such as neurotransmitter synthesis and
myelin production [1]. Iron levels in brain tissue are
found to be elevated in numerous neurological disor-
ders, including MS [1,3-7]. Pathogenesis of neurodegen-
erative disorders may be influenced by iron through the
promotion of oxidative stress, subsequently leading to
tissue damage [3,8]. Moreover, increased deposition of
non-hemin iron, predominantly in the basal ganglia, is
also related to the normal aging process [9,10]. Iron
deposition may derive from myelin/oligodendrocyte
debris, destroyed macrophages, or it can be the product
of hemorrhages from damaged brain vessels [1]. Oxida-
tive mitochondrial injury through Fenton reaction and
release of phospholipid-rich cellular membrane ele-
ments, with the generation of toxic free radicals, may
also be another important source of iron overload in
MS [11].
Recently, it was proposed in a pilot study that iron
deposits in MS may be related to chronic cerebrospinal
venous insufficiency (CCSVI), [6] a vascular condition
characterized by anomalies of the main extra-cranial
cerebrospinal venous routes that interfere with normal
blood outflow of brain parenchyma in patients with MS
[12]. The peculiarity of CCSVI-related cerebral venous
blood flow disturbances, together with the histology of
the perivenous spaces, leads to the hypothesis that iron
deposits in MS may be a consequence of chronic insuffi-
cient venous drainage [13,14]. According to this hypoth-
esis, an excessive amount of iron, due to altered
cerebrospinal venous return, may cause damage to the
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blood-brain-barrier and consequent disturbed microcir-
culation, leading to erythrocyte extravasation as a pri-
mary source of iron deposition in the form of micro
bleeds. In fact, histological and MRI studies confirm ery-
throcyte extravasation in a subset of brain plaques of
MS patients, and the presence of iron-laden macro-
phages at the perivenular level, with lesion progression
occurring along the venous vasculature [4,5,15-19]. It
has been observed that the cell involved in iron overload
with the greatest effect on immunity is the macrophage,
and there is a close relationship between iron and the
major cells of adaptive immunity, the T lymphocytes,
since they are major players in recycling the iron from
hemoglobin [20]. Therefore, iron may be a powerful
chemotactic stimulus that attracts macrophages and
contributes to or causes initial activation of T-cell auto-
immunity in patients with MS. On the other hand, an
alternative hypothesis could be that decreased blood
flow in brain parenchyma of MS patients could result
from vessel congestion or occlusion due to inflammatory
cells, fibrin deposits, or other factors [5,21]. In this case,
iron deposits could develop as a consequence of inflam-
matory reactions rather than causing them.
Williams et al., [2] developed their cEAE model by
giving a mouse an encephalitogen injection followed by
a stereotactic intracerebral injection of tumor necrosis
factor-alpha (TNF-a) and interferon-gamma (IFN-g). In
order to test whether iron deposition precedes inflam-
mation, they included 3 groups of control animals that
received encephalitogen followed by an intracerebral
injection of saline, or no encephalitogen plus an intra-
cerebral injection of saline or cytokines. They used laser
Doppler to measure cerebral blood flow, and MRI and
iron histochemistry to localize iron deposits. Addition-
ally, they utilized standard histology to localize inflam-
matory cell infiltrates, microgliosis and astrogliosis.
They report that inflammatory cell infiltrates are asso-
ciated with perivascular iron deposits; however inflam-
matory cells were also observed without associated iron
deposits. Consequently, they conclude that the develop-
ment of inflammatory cell infiltrates is not necessarily
dependent on iron deposition in this model. The pre-
sence of iron deposits around cerebral blood vessels is
observed predominantly in mice with cEAE, but not in
the control groups. This is an important finding, sug-
gesting that encephalitogenic activation of inflammatory
cells and their further enticement by cytokines is
required to initiate the iron deposition. Nevertheless,
what cannot be fully excluded from this study is
whether a condition like CCSVI may contribute to
increased iron deposition in MS, and if iron induced
endothelial damage at the level of blood-brain-barrier
may further lead to increased inflammation and neuro-
degeneration. In fact, recent studies suggest that CCSVI
is present only in some, but not all MS patients, and is
also present in healthy subjects and patients with other
neurologic diseases [22]. Moreover, the prevalence of
CCSVI is rare at first clinical onset, [22,23] but increases
with progression of the disease, strongly arguing against
a causative role [22,24].
Another important finding of the Williams et al. study,
[2] is that Doppler analysis revealed that cEAE mice had
a reduction in cerebral blood flow compared to controls,
which might be due to vessel congestion caused by
inflammatory cells. In addition, they found that inflam-
matory stimuli were accompanied by increased occur-
rence of iron deposition around vessels, although it was
independent of the degree of vessel stenosis. Vessel con-
gestion has also been noted in selected studies of MS,
[5,16,17,21] therefore, these findings support a patho-
genic mechanism whereby vascular inflammation leads
to alterations in CNS blood flow and consequent iron
deposition. Moreover, the average number of vessels per
animal that showed iron deposition without inflamma-
tion was actually significantly higher than the number of
vessels with inflammation and iron deposition suggest-
ing an independent progressive process related to iron
accumulation ensuing the initial inflammatory trigger.
Mice with cEAE also demonstrated increased astro-
gliosis and microgliosis, with reactive microglia staining
positively for iron [2]. However, iron deposits were not
required for the development of astrogliosis and micro-
gliosis around vessels, since these reactions were
observed in the absence of perivascular iron deposits. It
is possible that iron deposits could amplify MS patho-
genesis via these cells, since it has been demonstrated
that iron is taken up by perivascular microglia/macro-
phages in MS and EAE [3-5,18].
A potential critique of the model [2] is that focally
increased concentrations of TNF-a and IFN-g in the
brain occurring at the same time as the development of
an autoimmune myelin epitope response may not plau-
sibly occur spontaneously; however, the modification of
the immune response clearly has led to a model of focal
iron deposition in the brain in the context of inflamma-
tion. Dr. LeVine’s team reported similar iron deposition
in earlier publications without the need for the focal
brain injections [25] and it is not clear how their origi-
nal model compares to the currently reported model
from the standpoint of iron deposition.
Many uncertainties remain about the overall impor-
tance and contribution of iron deposition to inflamma-
tion (or vice versa) in the pathogenesis of MS. However,
the study by Williams et al. [2] provides important evi-
dence that inflammation may be unrelated to and can
precede iron deposition in cEAE. Further studies in
examining the association between inflammation and
iron deposition are needed to clarify this neglected area
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of MS research. These studies should establish the asso-
ciation between inflammation, reduced blood flow, iron
deposition, microglia activation and astrogliosis. The
study by Williams et al. [2] represents an important step
in studying the above relationship.
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